Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Prolia is a prescription medicine used to treat osteoporosis in women
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Encouraging early detection and breaking the silence around men’s health
The company is bringing precision therapies for gynaecological cancers
Subscribe To Our Newsletter & Stay Updated
